Skip to main content

Table 1 The relationship between serum CA19-9 levels and clinicopathological factors in 120 cases of PDAC treated by surgical resection

From: Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

Characteristics

Number (n = 120)

CA19-9 (Median, U/mL)

P value

Age (years): Median (Range)

60 (35-80)

  

 <60

57 (47.5%)

297.20

0.879

 ≥60

63 (52.5%)

243.00

 

Gender

   

 Male

67 (55.8%)

280.51

0.417

 Female

53 (44.2%)

294.70

 

Location of tumor

   

 Head

92 (76.7%)

294.95

0.782

 Body or tail

28 (23.3%)

242.30

 

Maximal tumor size (cm): Median (Range)

4.0 (1.2-10)

  

 <4.0

48 (40.0%)

227.65

0.193

 ≥4.0

72 (60.0%)

301.05

 

Differentiation

   

 well

41 (34.2%)

130.40

0.024

 moderately

68 (56.7%)

467.00

 

 poorly

11 (9.1%)

208.77

 

Surgical margins

   

 Negative

114 (95.0%)

295.95

0.087

 Positive

6 (5.0%)

109.23

 

pT category

   

 pT1 + pT2

58 (48.3%)

205.10

0.055

 pT3 + pT4

62 (51.7%)

328.60

 

pN category

   

 pN0

81 (67.5%)

250.00

0.403

 pN1

39 (32.5%)

328.80

 

pTNM category

   

 I

44 (36.7%)

205.10

0.161

 II

53 (44.2%)

304.90

 

 III

23 (19.1%)

558.80

 

Serum total bilirubin (μmol/L): Median (Range)

29.80 (2.80-507.30)

  

 <34.2 μmol/L (2.0 mg/dL)

63 (52.5%)

187.90

0.025

 ≥34.2 μmol/L (2.0 mg/dL)

57 (47.5%)

332.80